$XBI $71.79 | +2.51%
Table of Contents:
Covid Updates
#MDNA +14.4% Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron
Pipeline Updates
#VACC +38.2%
#OMER +34.7%
#ANEB +27.3%
#XXII +20.3%
#CBAY +16.5% CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022
#VBIV +14.4% VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
#BMEA +14.0% Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial
#RYTM +13.6% Rhythm Pharmaceuticals Launches IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency
#RYTM +13.6% Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREE® (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment
#MBIO +12.6% Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia
#RUBY +9.4% Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
#AVEO +8.8% AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
#TERN +7.2% TERNS PHARMACEUTICALS HIGHLIGHTS CLINICAL DATA FROM MULTIPLE NASH PROGRAMS IN FIVE PRESENTATIONS AT THE EASL INTERNATIONAL LIVER CONGRESS™ 2022
#KRYS +6.8% Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
#BBIO +6.0% BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
#IKNA +5.5% Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma
#XENE +5.3% Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program
#ZYNE +4.6% Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome
#ASMB +3.4% Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
#AXSM +3.0% Axsome Therapeutics to Host Sunosi® Investor Update Virtual Event
#BCRX +0.4% BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022
#SLS -0.4% SELLAS Life Sciences Reports Encouraging Updated Clinical Data Indicating Increased Survival from Ongoing Phase 1 Mesothelioma Study of Galinpepimut-S Combined with Opdivo
#RDUS -3.1% Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant
#VTGN -3.8% VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
#RMTI -3.8% Rockwell Medical Provides Corporate and Clinical Update
#SESN -11%
#ADXN -11.3%
#ARMP -12.1%
#ATHA -66.3% Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
#DTIL +7.2% Precision BioSciences Announces $50 Million Offering of Common Stock
#TNXP +3.8% Tonix Pharmaceuticals Announces Pricing of $30 Million Private Placement of Convertible Redeemable Preferred Stock
#ATNX 0.0% Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree
Posted by FS/JM
Comments